NIDA Clinical Trials Network: New York Node

NIDA 临床试验网络：纽约节点

基本信息

批准号：
10855627
负责人：
Jennifer McNeely
金额：
$ 286.74万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-03-01 至 2024-02-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10855627
关键词：
Academia Accident and Emergency department Address Adoption Advocacy Alaska Native Alcohols American Indians Ancillary Study Area Behavior Therapy Buprenorphine Caring Cities Clinic Clinical Clinical Management Clinical Trials Clinical Trials Network Collaborations Communities Criminal Justice Data Analytics Data Science Effectiveness Electronic Health Record Evidence based intervention Funding Future Generations Health Health Personnel Healthcare Systems Individual Infrastructure Injections Intervention Lead Long Island Mainstreaming Medical Mental disorders Minority Naltrexone National Institute of Drug Abuse New York Nicotine Opioid Patients Pharmaceutical Preparations Pharmacotherapy Policies Policy Maker Prevention Prevention trial Primary Care Provider Public Health Research Research Personnel Schedule Science Scientist Services Site Surveys Technology Training Translating Treatment outcome Vision Withdrawal Woman Work addiction community organizations digital health care settings health economics implementation facilitation implementation science improved innovation medical specialties metropolitan novel opioid epidemic opioid use opioid use disorder pre-exposure prophylaxis predictive modeling primary care provider stimulant dependence treatment program virtual

项目摘要

The New York Node (NYN) of the NIDA CTN, led by John Rotrosen and Edward Nunes, represents the 2010 merger of the New York and Long Island Nodes, which had been part of the CTN since 2000 and 2001, respectively. This fourth competing renewal application builds on both a strong and successful infrastructure to manage clinical trials, and a track record of innovation and successful implementation of trials in mainstream healthcare settings where most SUD patients are seen. We contribute expertise in virtually all key CTN priorities outlined in RFA-DA-20-024, including: integration of SUD treatment and prevention in mainstream settings (primary care, emergency departments, criminal justice); leveraging the electronic health record to support improved and expanded care; developing medications and behavioral therapies; co-occurring medical and psychiatric disorders; women and minorities; digital and other technology-based interventions; data science including novel data analytic approaches; and implementation science, health economics, advocacy, and policy to sustain evidence-based interventions. In the new funding period, the NYN will lead or co-lead seven ambitious projects, all scheduled to begin in 2019 or 2020: CTN-0079-A1 Ancillary Study of the Adoption and Sustainability of ED-Initiated Buprenorphine; CTN-0082 Implementation Survey of PrEP and Opioid Use Related Services in STI Clinics and Community Based Organizations; CTN-0094 Individual Level Predictive Modeling of Opioid Use Disorder Treatment Outcome; CTN-0096 Culturally Centered MAT for OUD Implementation Facilitation for Primary Care and Addiction Treatment Programs Serving American Indian/Alaska Natives; CTN-0097 Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder; CTN-0100 Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy; and CTN-0101 Subthreshold Opioid Use Disorder Prevention (STOP) Trial. We will also continue to help develop new trials in CTN, including in the area of stimulant dependence, and to supply sites for CTN trials. To support this, we have built a network of collaborating researchers, providers, and policy makers from academia, community-based addiction treatment programs, large multifaceted healthcare systems, and NY City and State agencies, all in the nation’s largest and most diverse metropolitan area. We have established a track record of substantial contributions to the CTN, building on our work through deliberate, rigorous, and stepwise improvements. Our vision for the Network’s future includes work built around addressing gaps highlighted by the opioid treatment cascade, interventions for stimulant dependence, effective use of the CTN platform to enable a broad range of non-CTN studies, and a continued commitment to training a new generation of addictions clinical researchers. Further, we partner with implementation scientists, health economists, advocacy groups, and policy experts to maximize the sustainability of effective new interventions.

由John Rotrosen和Edward Nunes领导的NIDA CTN的纽约节点（NYN）代表2010年自2000年和2001年以来一直是CTN的一部分，纽约和长岛节点的合并分别。第四次竞争的续订应用程序都建立在强大而成功的基础设施上管理临床试验，以及创新和成功实施主流试验的记录大多数SUD患者的医疗保健环境。我们在几乎所有关键CTN上都有贡献专业知识 RFA-DA-20-024中概述的优先级，包括：SUD治疗和预防的整合设置（初级保健，急诊部，刑事司法）；利用电子健康记录支持改善和扩大护理；开发药物和行为疗法；同时出现的医疗和精神疾病；妇女和少数民族；数字和其他基于技术的干预措施；数据科学在内，包括新颖的数据分析方法；以及实施科学，卫生经济学，倡导，以及维持基于证据的干预措施的政策。在新的资金期间，NYN将领导或共同领导七个雄心勃勃的项目，原定于2019年或2020年开始：CTN-0079-A1采用辅助研究和启发的丁丙诺啡的可持续性； CTN-0082 PREP和阿片类药物使用的实施调查 STI诊所和社区组织的相关服务； CTN-0094个人级别预测阿片类药物使用障碍治疗结果的建模； CTN-0096以文化为中心的垫子初级保健和成瘾治疗计划的实施便利，为美国的服务印度/阿拉斯加本地人； CTN-0097超越戒断以开始使用纳曲酮（SWIFT）快速治疗：提高注射纳曲酮对阿片类药物使用障碍的现实有效性； CTN-0100优化阿片类药物使用障碍药物治疗的保留，持续时间和中断策略；和CTN-0101 亚阈值预防障碍（Stop）试验。我们还将继续帮助开发新的试验 CTN，包括在兴奋剂依赖性领域以及为CTN试验提供位点。为了支持这一点，我们建立了一个由合作的研究人员，提供者和政策制定者的网络学术界，基于社区的成瘾治疗计划，大型多面医疗保健系统和纽约城市和州机构，都是美国最大，最多样化的大都市地区。我们已经建立了对CTN的实质性贡献的记录，通过故意，严格和逐步改进。我们对网络未来的愿景包括围绕解决空白的工作由阿片类药物治疗级联突出显示，刺激依赖性的干预措施，有效地使用CTN 平台实现广泛的非CTN研究，并继续致力于培训新的研究成瘾的产生临床研究人员。此外，我们与实施科学家合作，健康经济学家，倡导团体和政策专家，以最大化有效的新干预措施的可持续性。

项目成果

期刊论文数量（155）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Social functioning outcomes among individuals with substance use disorders receiving internet-delivered community reinforcement approach.

接受互联网提供的社区强化方法的药物滥用障碍患者的社会功能结果。

DOI：
10.1080/10826084.2018.1528458
发表时间：
2019
期刊：
Substance use & misuse
影响因子：
2
作者：
Marino,LA;Campbell,ANC;Pavlicova,M;Hu,M;Nunes,EV
通讯作者：
Nunes,EV

Stepped-wedge randomized controlled trial of a novel opioid court to improve identification of need and linkage to medications for opioid use disorder treatment for court-involved adults.

DOI：
10.1016/j.jsat.2021.108277
发表时间：
2021-09
期刊：
Journal of substance abuse treatment
影响因子：
3.9
作者：
Elkington KS;Nunes E;Schachar A;Ryan ME;Garcia A;Van DeVelde K;Reilly D;O'Grady M;Williams AR;Tross S;Wilson P;Cohall R;Cohall A;Wainberg M
通讯作者：
Wainberg M

The Opioid/Overdose Crisis as a Dialectics of Pain, Despair, and One-Sided Struggle.

DOI：
10.3389/fpubh.2020.540423
发表时间：
2020
期刊：
Frontiers in public health
影响因子：
5.2
作者：
Friedman SR;Krawczyk N;Perlman DC;Mateu-Gelabert P;Ompad DC;Hamilton L;Nikolopoulos G;Guarino H;Cerdá M
通讯作者：
Cerdá M

Trajectories of depression among patients in treatment for opioid use disorder: A growth mixture model secondary analysis of the XBOT trial.

阿片类药物使用障碍患者的抑郁轨迹：XBOT 试验的生长混合模型二次分析。

DOI：
10.1111/ajad.13371
发表时间：
2023
期刊：
The American journal on addictions
影响因子：
0
作者：
Vest,Noel;Wenzel,Kevin;Choo,Tse-Hwei;Pavlicova,Martina;Rotrosen,John;Nunes,Edward;Lee,JoshuaD;Fishman,Marc
通讯作者：
Fishman,Marc

Computational theory-driven studies of reinforcement learning and decision-making in addiction: What have we learned?